The routine determination of the endogenous thrombin potential, first results in different forms of hyper- and hypocoagulability

Thrombosis and Haemostasis

Volumn 77, Issue 4, 1997, Pages 629-636

  Wielders, Simone ^a   Mukherjee, Manjari ^b   Michiels, Jan ^c   Rijkers, Dirk T S ^a   Cambus, Jean Pierre ^d   Knebel, Richard W C ^e   Kakkar, Vijay ^b   Hemker, H Coenraad ^a,b   Béguin, Suzette ^a,b  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b THROMBOSIS RESEARCH INSTITUTE   (United Kingdom)

^c Afd Klinische Pathologie   (Netherlands)

^d CHU RANGUEIL   (France)

^e HÔPITAL BROUSSAIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ELLAGIC ACID; ENOXAPARIN; ORAL CONTRACEPTIVE AGENT; THROMBIN; THROMBOPLASTIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; HYPERCOAGULABILITY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SCREENING TEST; THROMBOSIS;

EID: 0030896076     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1656024     Document Type: Article

References (35)

1. Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medizin. Berlin: Max Hirsch Verlag 1962; pp 294.
2. Biggs R, Macfarlane RG. Human Blood Coagulation and its Disorders. Oxford: Blackwell Scientific Publications 1967; pp 67.
3. Hemker HC. Thrombin Generation, an Essential Step in Haemostasis and Thrombosis. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds). Haemostasis and Thrombosis. Edinburgh: Churchill Livingstone 1993; pp 477-90.
4. Hemker HC, Wielders SJH, Kessels H, Béguin S. Continuous registration of thrombin generation in plasma, Its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
5. Hemker HC, Béguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 1995; 74: 134-8.
6. Hemker HC, Willems GM, Béguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes. Thromb Haemost 1986; 56: 9-17.
7. Jochmans K, Lissens W, Ting Yin, Michiels JJ, Van der Luit L, Peerlinck K, De Waele M, Liebaers I. Molecular basis for type 1 antithrombin deficiency: Identification of two novel point mutations and evidence for a de novo splice site mutation. Blood 1994; 84: 3742-8.
8. Michiels JJ, Van der Luit L, Van Vliet HHDM, Jochmans K, Lissens W. Nonsense mutation Arg197 stop in a dutch family with type 1 hereditary antithrombin deficiency causing thrombophylia. Thromb Res 1994; 78: 251-6.
9. Engel H, Zwang L, Van Vliet HHDM, Michiels JJ, Stibbe J, Lindemans J. Phenotyping and genotyping of coagulation factor V Leiden. Thromb Haemost 1996; 75: 267-8.
10. Rijkers DTS, Adams HPHM, Hemker HC, Tesser GI. A convenient synthesis of amino acid p-nitroanilides, synthons in the synthesis of protease substrates. Tetrahedron 1995; 51: 11235-50.
11. Rijkers DTS, Wielders SJH, Tesser GI, Hemker HC. Design and synthesis of thrombin substrates with modified kinetic parameters. Thromb Res 1995; 79: 491-9.
12. Chan KE, Rizza CR, Henderson MP. A study on the coagulant properties of Malayan pit-viper venom. Br J Haemat 1965; 11: 646-57.
13. Davey MG, Luscher EF. Actions of some coagulant snake venoms on blood platelets. Nature 1965; 207: 730.
14. Bendetowicz AV, Béguin S, Caplain H, Hemker HC. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (Enoxaparin) after subcutaneous injection, comparison with unfractionated heparin. A three way cross over study in human volunteers. Thromb Haemost 1994; 71: 305-13.
15. 2-macroglobulin inactivating enzymes from the venom of the mexican west coast rattlesnake (Crotalus basilicus). Toxicon 1995; 33: 1331-46.
16. Lindhout T, Blezer R, Hemker HC. The anticoagulant mechanism of action of recombinant hirudin (CGP 39393) in plasma. Thromb Haemost 1990; 64: 464-8.
17. Nemerson Y. Tissue factor, then and now. Thromb Haemost 1995; 74: 180-4.
18. Morissey JH. Tissue factor modulation of factor VII avtivity. Thromb Haemost 1995; 74: 185-8.
19. Béguin S, Lindhout T, Hemker HC. The mode of action of heparin in plasma. Thromb Haemost 1988; 60:457-62.
20. Von dem Borne PAKr, Meijers JCM, Bouma BM. Feedback activation of Factor XI in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-42.
21. Bajzàr L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1995; 270: 14477-84.
22. Barrowcliffe TW, Johnson FJ, Thomas DP. Low Molecular Weight Heparin. Chichester: John Wiley & Sons 1992; pp 135.
23. Levine NM, Hirsh J, Gent M, Turpie AG, Cruickshank M, Weitz J, Anderson D, Johnson M. A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venoembolism requiring large daily doses of heparin. Arch Intern Med 1994; 154: 49-56.
24. Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Bayliss B, Ginsberg JS, Panju AA, Brill-Edwards P, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-95.
25. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Path 1993; 100: 94-8.
26. Van der Velde EA, Poller L. The APTT monitoring of heparin - The ISTH/ICSH Collaborative study. Thromb Haemost 1995; 73: 73-81.
27. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
28. Sandset PM, Abildgaard U. Extrinsic pathway inhibitor - the key to feedback control of blood coagulation initiated by tissue thromboplastin. Haemostasis 1991; 21: 219-39.
29. Hemker HC, Béguin S. Standard- and Method Independent Units for Heparin Anticoagulant Activities. Thromb Haemost 1993; 70: 724-8.
30. ++ Ions; why the Anti-Xa Activity of LMW Heparins Is about two Times Overestimated. Thromb Haemost 1993; 70: 717-8.
31. Van den Besselaar AMHP. Recommended method for reporting therapeutic control of oral anticoagulant therapy. Thromb Haemost 1990; 63: 316-7.
32. Hirsh J. Optimal Therapeutic Ranges for Unfractionated Heparin and Low Molecular Weight Heparins. In: Fuster V, Verstraete M (eds). Thrombosis in Cardiovascular Disorders. Philadelphia: W. B. Saunders 1992; pp 147.
33. Aïach M, Michaud A, Capron L, Fiessinger JN. Determination of factor X and heparin with chromogenic substrate. Acta Chir Scand Suppl 1982; 509: 109-13.
34. Rotteveel RC, Roozendaal KJ, Eijsman L, Hemker HC. The influence of oral contraceptives on the time-integral of thrombin generation (Thrombin Potential). Thromb Haemost 1993; 70: 959-62.
35. Berends F, Morriën-Salomons WM, Van Enk A, Béguin S, Van den Ende A. Oral contraceptives induce the prethrombotic state. Thromb Haemost 1995; 73: 959 (abstr).